Publications by authors named "L Lacombe"
Article Synopsis
- The study investigates the role of 11-oxygenated androgens, particularly 11-ketotestosterone (11KT), in predicting the progression of lethal prostate cancer and the onset of castration-resistant prostate cancer (CRPC).
- Using mass spectrometry on blood samples from 145 patients treated with androgen deprivation therapy, researchers analyzed the relationship between androgen levels and CRPC development.
- Findings suggest higher levels of 11KT are associated with a shorter time to CRPC, indicating that monitoring this hormone could enhance treatment strategies for prostate cancer patients.
Article Synopsis
- This study looks at different types of immune cells in prostate cancer and how they affect the patient's chance of recovery.
- Researchers used lab tests on cancer samples to find out which immune cells are present and how they relate to the severity of the disease.
- They found that certain immune cell types and their amounts could predict if a patient would need more treatment or if the cancer could be deadly.
Article Synopsis
- Scientists studied the estrogen receptor α (ERα) in prostate cancer and found it only appears in about half of the patients' tumors.
- When ERα is present, it can affect how the cancer grows and spreads, and is linked to patients' chances of survival.
- The research suggests that targeting ERα could be a new way to treat prostate cancer by changing how cancer cells use energy.
Objectives: To evaluate the International Society of Urological Pathology (ISUP) 5-tier grade grouping (GG) system of prostate cancers as well as previously proposed optimizations.
Patients And Methods: The PROCURE biobank is a prospective cohort study of patients with localized prostate cancer who underwent radical prostatectomy in Quebec province between 2005 and 2013. Surgical specimens were graded by experienced genitourinary pathologists using 2019 ISUP criteria.
Background: High prostate eicosapentaenoic fatty acid (EPA) levels were associated with a significant reduction of upgrading to grade group (GG) ≥ 2 prostate cancer in men under active surveillance. We aimed to evaluate the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation.
Methods: A phase II double-blind randomized placebo-controlled trial was conducted in 130 men diagnosed with GG ≥ 2 prostate cancer and undergoing radical prostatectomy between 2015-2017 (Clinicaltrials.